Compare Fabrinet (FN) vs BIO-TECHNE Corp (TECH) Price & Performance

Fabrinet (FN) trades at $497.99, up 1.81% on the day, with a bullish technical signal and strong analyst support. The stock benefits from surging AI data center demand, evidenced by three consecutive quarterly earnings beats and robust revenue growth. Valuation ratios are elevated, but profitability metrics like a 21.33% ROE and expanding margins highlight operational strength. Recent news emphasizes capacity expansion to capture multi-year growth opportunities in optical manufacturing.

The outlook is positive, driven by AI infrastructure demand and earnings momentum, though risks include customer concentration and high capital expenditures. With a consensus price target of $769.50 implying significant upside, Wall Street remains bullish, but investors should monitor execution on growth initiatives and competitive pressures.

TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.

The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.